title: Randomized Clinical Trial to Compare Micropulse Photocoagulation Versus Half-dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy.
abstract: OBJECTIVE
  To evaluate subthreshold diode-laser micropulse (SDM) versus half-dose verteporfin photodynamic therapy (hd-PDT) in central serous chorioretinopathy (CSC).
  
  
  METHODS
  62 eyes of 62 patients were prospectively followed for changes in fluorescein angiography (FA), fundus autofluorescence (FAF), central macular thickness (CMT), best-corrected visual acuity (BCVA), and contrast visual acuity (CVA) after SDM (n=20) or hdPDT (n=24). CSC observation served as control group (n=18).
  
  
  RESULTS
  Both treatment groups (60% SDM vs. 66.7% hdPDT) showed significant improvement in reduction of leakage activity compared to the control group (37.5%) at 16 weeks. CMT decreased by 69.7 µm (SDM), 109.8 µm (hdPDT), and 89 µm (control). BCVA improved by +6.7 (SDM group), +8.5 (hdPDT), and +1.5 ETDRS letters (control). CVA was best improved in the hdPDT group. No secondary RPE alterations could be detected by FAF after any intervention.
  
  
  CONCLUSIONS
  In comparison to the control group, hdPDT and SDM resulted in reduced leakage activity in FA and enhanced photopic and scotopic visual acuity in patients with CSC.
authors.forename: Florian T A
authors.initials: FT
authors.lastname: Kretz
authors.forename: Isabell
authors.initials: I
authors.lastname: Beger
authors.forename: Frank
authors.initials: F
authors.lastname: Koch
authors.forename: Katarrzyna
authors.initials: K
authors.lastname: Nowomiejska
authors.forename: Gerd U
authors.initials: GU
authors.lastname: Auffarth
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Koss
mesh_terms: D000368:Aged; D002199:Capillary Permeability; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D017075:Laser Coagulation / Q000379:methods*; D054023:Lasers, Semiconductor / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D012171:Retinal Vessels / Q000473:pathology; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin